Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,287,033 papers from all fields of science
Search
Sign In
Create Free Account
Trial Phase 3A
Known as:
3A
, Phase IIIa Trial
, Trial Phase IIIA
A classification typically assigned retrospectively to a Phase III trial after regulatory authorities determined the need for a Phase III B trial.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
CDISC SDTM Trial Phase Terminology
Clinical Data Interchange Standards Consortium Terminology
Broader (1)
Research Activities
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Mei Yu
,
A. Corsa
,
+7 authors
G. Cheng
Antiviral Research
2013
Corpus ID: 23068627
Highly Cited
2009
Highly Cited
2009
Oxidative stress-specific interaction between FANCD2 and FOXO3a.
J. Li
,
W. Du
,
S. Maynard
,
P. Andreassen
,
Q. Pang
Blood
2009
Corpus ID: 9772194
The molecular pathway by which Fanconi anemia (FA) proteins function in oxidative stress response has not been defined. Here we…
Expand
2009
2009
Response rates to standard interferon treatment in HCV genotype 3a.
S. Qureshi
,
Uzma Batool
,
+4 authors
Muhammad Azhar
Journal of Ayub Medical College
2009
Corpus ID: 45970887
BACKGROUND Chronic Hepatitis C infection infects almost 130 to 170 million or approximately 2.2-3% of world's population. HCV is…
Expand
2008
2008
Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India.
V. Verma
,
A. Chakravarti
,
P. Kar
Diagnostic microbiology and infectious disease
2008
Corpus ID: 19783964
Highly Cited
2006
Highly Cited
2006
Impact of liver steatosis on the antiviral response in the hepatitis C virus‐associated chronic hepatitis
M. Soresi
,
S. Tripi
,
+5 authors
G. Montalto
Liver international (Print)
2006
Corpus ID: 24588115
Abstract: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects…
Expand
2004
2004
A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences.
E. Hsi
,
I. Mirza
,
+4 authors
R. Coupland
Archives of Pathology & Laboratory Medicine
2004
Corpus ID: 38023999
CONTEXT The World Health Organization classification recommends categorizing grade 3 follicular lymphomas based on the presence…
Expand
2001
2001
Integration of microstructural and functional aspects of human somatosensory areas 3a, 3b, and 1 on the basis of a computerized brain atlas
Stefan Geyer
,
A. Schleicher
,
+4 authors
K. Zilles
Anatomy and Embryology
2001
Corpus ID: 23893442
In this study we analyzed structural and functional aspects of the human primary somatosensory areas 3a, 3b, and 1 on the basis…
Expand
2001
2001
Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men.
A. Wu
,
A. Whittemore
,
+4 authors
D. West
Cancer Epidemiology, Biomarkers and Prevention
2001
Corpus ID: 4308222
Men with higher endogenous 5alpha-reductase activity may have higher prostate cancer risk. This hypothesis raises two questions…
Expand
1996
1996
Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio.
S. Mihm
,
H. Hartmann
,
A. Fayyazi
,
G. Ramadori
Digestive Diseases and Sciences
1996
Corpus ID: 7304742
Hepatitis C virus infection causes acute and often chronic hepatitis. Therapy with interferon-alpha has been shown to induce…
Expand
1994
1994
Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation.
L. Moonen
,
S. Horenblas
,
J. van der Voet
,
M. Nuyten
,
H. Bartelink
British Journal of Urology
1994
Corpus ID: 45222611
OBJECTIVE To retrospectively analyse the efficacy and toxicity of conservative treatment for T1G3 and T2-3a bladder carcinoma and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required